Parkinson’s is a debilitating condition with no current disease-modifying treatments available. We are now co-funding a phase 2 trial of dapansutrile, a novel anti-inflammatory drug with preliminary evidence that suggests it may reduce neuroinflammation and slow Parkinson’s progression.
Categories
Beneficiaries
Situation
Approximately 153,000 people in the UK are living with Parkinson’s, a neurological condition caused by the loss of dopamine-producing nerve cells in the brain. People with Parkinson’s experience a variety of symptoms, including tremor, muscle stiffness, exhaustion and depression, which makes even day-to-day activities increasingly difficult. Despite being the fastest growing neurological condition in the world, there is no cure and there are limited treatment options. We want to change this.
Solution
At Cure Parkinson’s, we fund pioneering research to develop therapies that aim to slow, stop or reverse Parkinson’s. We are now funding a phase 2 clinical trial of dapansutrile (DAPA-PD), an anti-inflammatory drug, to determine whether it has the potential to slow the progression of Parkinson’s. The trial will take place in the UK and will involve 36 people with Parkinson’s over a twelve-month period. Our sole aim is to find a cure – this trial could bring us closer to achieving this.
